NASDAQ:IDXG - Interpace Diagnostics Group Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $0.9460 +0.02 (+2.16 %) (As of 07/16/2018 06:48 AM ET)Previous Close$0.9230Today's Range$0.92 - $0.958052-Week Range$0.72 - $1.80Volume496,560 shsAverage Volume245,123 shsMarket Capitalization$26.36 millionP/E Ratio-1.17Dividend YieldN/ABeta1.83 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Interpace Diagnostics Group, Inc. develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinder platform; ThyGenX, an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules. The company's customers consist primarily of physicians, hospitals, and clinics. The company was formerly known as PDI, Inc. and changed its name to Interpace Diagnostics Group, Inc. in December 2015. Interpace Diagnostics Group, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey. Receive IDXG News and Ratings via Email Sign-up to receive the latest news and ratings for IDXG and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Services SectorMedical SymbolNASDAQ:IDXG CUSIP69329V10 Webwww.interpacediagnostics.com Phone855-776-6419 Debt Debt-to-Equity RatioN/A Current Ratio2.59 Quick Ratio2.59 Price-To-Earnings Trailing P/E Ratio-1.17 Forward P/E Ratio-2.56 P/E GrowthN/A Sales & Book Value Annual Sales$15.90 million Price / Sales1.66 Cash FlowN/A Price / CashN/A Book Value$1.48 per share Price / Book0.64 Profitability EPS (Most Recent Fiscal Year)($0.81) Net Income$-12,210,000.00 Net Margins-103.40% Return on Equity-46.58% Return on Assets-33.66% Miscellaneous Employees75 Outstanding Shares27,870,000Market Cap$26.36 Interpace Diagnostics Group (NASDAQ:IDXG) Frequently Asked Questions What is Interpace Diagnostics Group's stock symbol? Interpace Diagnostics Group trades on the NASDAQ under the ticker symbol "IDXG." How were Interpace Diagnostics Group's earnings last quarter? Interpace Diagnostics Group Inc (NASDAQ:IDXG) released its earnings results on Tuesday, May, 15th. The business services provider reported ($0.11) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.08) by $0.03. The business services provider earned $4.81 million during the quarter, compared to the consensus estimate of $4.30 million. Interpace Diagnostics Group had a negative net margin of 103.40% and a negative return on equity of 46.58%. View Interpace Diagnostics Group's Earnings History. What price target have analysts set for IDXG? 4 equities research analysts have issued 1-year price targets for Interpace Diagnostics Group's shares. Their forecasts range from $2.25 to $4.50. On average, they expect Interpace Diagnostics Group's stock price to reach $3.1875 in the next year. This suggests a possible upside of 236.9% from the stock's current price. View Analyst Ratings for Interpace Diagnostics Group. What is the consensus analysts' recommendation for Interpace Diagnostics Group? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Interpace Diagnostics Group in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." What are Wall Street analysts saying about Interpace Diagnostics Group stock? Here are some recent quotes from research analysts about Interpace Diagnostics Group stock: 1. According to Zacks Investment Research, "Interpace Diagnostics Group, Inc. provides molecular diagnostic tests. The company's test consists of ThyGenX Thyroid Oncogene Panel (R), Thyroid miRNA(TM) and PancraGen(TM). Interpace Diagnostics Group Inc, formerly known as PDI Inc., is headquartered in Parsippany, New Jersey. " (6/30/2018) 2. Maxim Group analysts commented, "Expansion of reimbursement contracts for molecular tests continues. The company announced that Blue Cross Blue Shield of Florida (private), its largest health plan, is now offering coverage for ThyGenX and ThyraMIR." (6/11/2018) Who are some of Interpace Diagnostics Group's key competitors? Some companies that are related to Interpace Diagnostics Group include Sensus Healthcare (SRTS), Invuity (IVTY), Restoration Robotics (HAIR), Alphatec (ATEC), Invo Bioscience (IVOB), Neovasc (NVCN), Arch Therapeutics (ARTH), Spectral Medical (EDTXF), CAS Medical Systems (CASM), SANUWAVE Health, Inc. Common Stock (SNWV), iCAD (ICAD), Repro-Med Systems (REPR), Nephros (NEPH), Valeritas (VLRX) and CELLECT BIOTECH/S (APOP). Who are Interpace Diagnostics Group's key executives? Interpace Diagnostics Group's management team includes the folowing people: Mr. Jack E. Stover, CEO, Pres and Director (Age 65)Mr. James E. Early, CFO, Sec. & Treasurer (Age 64)Mr. Gregory Richard, Sr. VP & Chief Commercial Officer (Age 51)Mr. Thomas John Freeburg, Chief Accounting Officer (Age 50)Mr. Patrick Kane, VP & Corp. Controller Has Interpace Diagnostics Group been receiving favorable news coverage? Press coverage about IDXG stock has been trending somewhat positive on Monday, Accern reports. The research group scores the sentiment of news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Interpace Diagnostics Group earned a coverage optimism score of 0.12 on Accern's scale. They also assigned news articles about the business services provider an impact score of 46.06 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. How do I buy shares of Interpace Diagnostics Group? Shares of IDXG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Interpace Diagnostics Group's stock price today? One share of IDXG stock can currently be purchased for approximately $0.9460. How big of a company is Interpace Diagnostics Group? Interpace Diagnostics Group has a market capitalization of $26.36 million and generates $15.90 million in revenue each year. The business services provider earns $-12,210,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis. Interpace Diagnostics Group employs 75 workers across the globe. How can I contact Interpace Diagnostics Group? Interpace Diagnostics Group's mailing address is MORRIS CORPORATE CENTER 1 BUILDING C 300 INTERPACE PARKWAY, PARSIPPANY NJ, 07054. The business services provider can be reached via phone at 855-776-6419 or via email at [email protected] MarketBeat Community Rating for Interpace Diagnostics Group (NASDAQ IDXG)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 143 (Vote Outperform)Underperform Votes: 111 (Vote Underperform)Total Votes: 254MarketBeat's community ratings are surveys of what our community members think about Interpace Diagnostics Group and other stocks. Vote "Outperform" if you believe IDXG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IDXG will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/16/2018 by MarketBeat.com StaffFeatured Article: What does relative strength index mean?